2020
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalence
2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso
Somé A, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A, Zongo M, Compaoré Y, Ouédraogo J. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite 2016, 23: 60. PMID: 28004634, PMCID: PMC5178381, DOI: 10.1051/parasite/2016069.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, BacterialAntigens, SurfaceAntimalarialsArtemisininsBurkina FasoChildChild, PreschoolDrug ResistanceDrug Therapy, CombinationHumansInfantMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsYoung AdultConceptsPolymerase chain reactionUncomplicated malariaDrug resistance polymorphismsPfcrt 76TResistance-mediating polymorphismsPrevalence of polymorphismsSymptomatic malaria patientsAntimalarial drug resistanceGlobal malaria controlEmergence of resistancePfmdr1 184FPfmdr1 86YMalaria patientsPfdhps genesBaseline prevalenceCombination therapyHealth centersBlood samplesWestern CambodiaBetter efficacyGene polymorphismsCodon 540Malaria controlDrug resistancePfdhps
2014
Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso
Somé A, Zongo I, Compaoré Y, Sakandé S, Nosten F, Ouédraogo J, Rosenthal P. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2014, 58: 3660-3665. PMID: 24733476, PMCID: PMC4068591, DOI: 10.1128/aac.02406-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAQ/SPMalaria chemopreventionSingle nucleotide polymorphismsP. falciparum crtPfcrt 76TResistance-mediating polymorphismsMalaria control measuresPCR-positive samplesMonthly DPPfdhfr 108NPfdhfr 51IPfmdr1 86YSulfadoxine-pyrimethamineTreatment armsDevelopment of resistanceTransmission seasonControl groupP. falciparumSNP prevalenceGenetic polymorphismsRegular useAntifolate antimalarialsMonthsBurkina Faso